Johnson & Johnson’s Rybrevant Faspro (amivantamab-vmjw plus chemotherapy administration details not provided in the source) won accelerated FDA approval for advanced head and neck cancer after prior chemotherapy and immunotherapy. The decision expands use beyond its earlier approval setting and signals continued momentum for bispecific antibody strategies in hard-to-treat solid tumors. The accelerated pathway underscores the regulator’s reliance on earlier clinical endpoints, with confirmatory evidence expected in follow-on trials. For oncology pipeline planning, the approval also raises competitive pressure around HER-family targeting and bispecific mechanisms already in late-stage development. Market participants will likely focus on how Rybrevant Faspro fits in the post–chemo/immune landscape, including sequencing questions for patients who have progressed after standard regimens.